A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine as a Booster Dose in Population Aged 12-17 Years
Phase 2
- Conditions
- COVID-19SARS-CoV-2 Infection
- Interventions
- Biological: mRNA-1273Biological: SCTV01E
- First Posted Date
- 2022-04-26
- Last Posted Date
- 2022-04-26
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 300
- Registration Number
- NCT05345873
A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine in Population Aged β₯18 Years
Phase 2
- Conditions
- SARS-CoV-2 InfectionCOVID-19
- Interventions
- Biological: SCTV01EBiological: Comirnaty
- First Posted Date
- 2022-04-14
- Last Posted Date
- 2022-04-14
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 400
- Registration Number
- NCT05329051
A Study to Evaluate the Immunogenicity and Safety of Two Recombinant Protein COVID-19 Vaccines in Population Aged β₯18 Years as Booster Vaccines
Phase 3
Active, not recruiting
- Conditions
- COVID-19SARS-CoV-2 Infection
- Interventions
- Biological: Sinopharm inactivated COVID-19 vaccineBiological: SCTV01EBiological: SCTV01CBiological: Comirnaty
- First Posted Date
- 2022-04-12
- Last Posted Date
- 2023-04-10
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 1800
- Registration Number
- NCT05323461
- Locations
- π¦πͺ
Al Kuwait Hospital (Al Baraha Hospital), Dubai, United Arab Emirates
A Study to Evaluate the Efficacy and Safety of SCTV01E (a COVID-19 Vaccine) in Population Aged β₯18 Years
Phase 3
Active, not recruiting
- Conditions
- COVID-19SARS-CoV-2 Infection
- Interventions
- Biological: SCTV01EBiological: Placebo
- First Posted Date
- 2022-04-04
- Last Posted Date
- 2024-04-15
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 10000
- Registration Number
- NCT05308576
- Locations
- π¨π³
Guizhou center for disease control and prevention, Guiyang, Guizhou, China
A Study to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E (Two Recombinant Protein COVID-19 Vaccines) in Population Aged β₯12 Years
Phase 2
Withdrawn
- Conditions
- COVID-19SARS-CoV-2 Infection
- Interventions
- Biological: mRNA vaccine manufactured by Pfizer or ModernaBiological: SCTV01CBiological: SCTV01EBiological: Sinopharm inactivated COVID-19 vaccine
- First Posted Date
- 2022-04-04
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- Sinocelltech Ltd.
- Registration Number
- NCT05308602
A Study of the Immunogenicity and Safety of SCTV01C in Population Aged β₯12 Years and Previously Vaccinated With Inactivated COVID-19 Vaccine
Phase 2
Withdrawn
- Conditions
- COVID-19SARS-CoV2 Infection
- Interventions
- Biological: ComirnatyBiological: SCTV01C
- First Posted Date
- 2022-02-15
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- Sinocelltech Ltd.
- Registration Number
- NCT05239975
A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E in Population Aged β₯12 Years Previously Fully Vaccinated With Inactivated COVID-19 Vaccine
Phase 2
- Conditions
- COVID-19SARS-CoV-2 Infection
- Interventions
- Biological: SCTV01CBiological: ComirnatyBiological: Sinopharm inactivated COVID-19 vaccineBiological: SCTV01E
- First Posted Date
- 2022-02-15
- Last Posted Date
- 2022-04-11
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 400
- Registration Number
- NCT05239806
A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C in Population Aged β₯18 Years and Previously Fully Vaccinated With COVID-19 Vaccine
Phase 2
- Conditions
- SARS-CoV-2 InfectionCOVID-19
- Interventions
- Biological: SCTV01CBiological: Sinopharm inactivated COVID-19 vaccineBiological: Comirnaty
- First Posted Date
- 2022-02-14
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 600
- Registration Number
- NCT05238454
A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01E in Population Aged β₯18 Years Previously Fully Vaccinated With mRNA COVID-19 Vaccine
Phase 2
- Conditions
- COVID-19Sars-CoV-2 Infection
- Interventions
- Biological: SCTV01EBiological: Comirnaty
- First Posted Date
- 2022-02-14
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 360
- Registration Number
- NCT05238441
A Study to Evaluate Efficacy and Safety of the Combination of SCTA01 & SCTA01C in Outpatients With COVID-19
Phase 1
Withdrawn
- Conditions
- COVID-19
- Interventions
- Drug: SCTA01 and SCTA01CDrug: Placebo
- First Posted Date
- 2021-12-14
- Last Posted Date
- 2022-01-27
- Lead Sponsor
- Sinocelltech Ltd.
- Registration Number
- NCT05156645
Β© Copyright 2025. All Rights Reserved by MedPath